

**Wright Medical Group N.V.**  
**Supplemental Net Sales Information**  
(unaudited)

**Three months ended March 26, 2017 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	0%	(8%)	(12%)	(2%)	(2%)
Upper extremities	12%	10%	7%	11%	10%
Biologics	9%	24%	23%	12%	12%
Sports med & other	(2%)	0%	(6%)	0%	(4%)
<b>Total net sales</b>	<b>6%</b>	<b>4%</b>	<b>1%</b>	<b>6%</b>	<b>5%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	<b>Three months ended</b>	
	<b><u>March 26, 2017</u></b>	<b><u>March 27, 2016</u></b>
<b>Gross profit from continuing operations, as reported</b>	<b>\$ 140,065</b>	<b>\$ 122,625</b>
<b>Gross margins from continuing operations, as reported</b>	<b>79.0 %</b>	<b>72.4 %</b>
Reconciling items impacting gross profit:		
Inventory step-up amortization	—	10,229
Transaction and transition costs	685	124
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 140,750</b>	<b>\$ 132,978</b>
Net sales from continuing operations	177,191	169,291
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>79.4%</b>	<b>78.5%</b>

**Wright Medical Group N.V.**

**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share**

(dollars in thousands, except per share data--unaudited)

	<b>Three months ended</b>	
	<b>March 26, 2017</b>	<b>March 27, 2016</b>
<b>Net loss from continuing operations, as reported</b>	\$ (36,707)	\$ (40,193)
<b>Net loss from continuing operations per share, as reported</b>	\$ (0.35)	\$ (0.39)
Reconciling items:		
Inventory step-up amortization	—	10,229
Non-cash interest expense on convertible notes <sup>1</sup>	10,999	7,056
Derivatives mark-to-market adjustments <sup>2</sup>	365	(6,641)
Transaction and transition costs	2,972	10,833
CVR mark-to-market adjustments <sup>2</sup>	6,160	5,324
Tax effect of reconciling items <sup>3</sup>	(18)	(1,189)
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	\$ (16,229)	\$ (14,581)
Add back amortization of intangible assets	7,397	6,457
<b>Adjusted non-GAAP earnings</b>	\$ (8,832)	\$ (8,124)
Weighted-average basic shares outstanding	103,663	102,704
<b>Adjusted non-GAAP earnings per share</b>	\$ (0.09)	\$ (0.08)

<sup>1</sup> Impacting interest expense, net

<sup>2</sup> Impacting other expense (income), net

<sup>3</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended	
	March 26, 2017	March 27, 2016
<b>Net loss from continuing operations</b>	\$ (36,707)	\$ (40,193)
Interest expense, net	18,195	11,854
Provision (benefit) from income taxes	939	(1,287)
Depreciation	13,446	12,850
Amortization	7,397	6,457
<b>Non-GAAP EBITDA</b>	<b>\$ 3,270</b>	<b>\$ (10,319)</b>
Reconciling items impacting EBITDA:		
Non-cash share-based compensation expense	3,954	3,317
Other expense (income), net	7,975	(1,068)
Inventory step-up amortization	—	10,229
Transaction and transition costs	2,972	10,833
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 18,171</b>	<b>\$ 12,992</b>
Net sales from continuing operations	177,191	169,291
<b>Non-GAAP adjusted EBITDA margin</b>	<b>10.3%</b>	<b>7.7%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	Three months ended	
	March 26, 2017	March 27, 2016
<b>Net sales</b>	\$ 177,191	\$ 169,291
<b>Selling, general and administrative expense, as reported</b>	\$ 129,834	\$ 134,746
Selling, general and administrative expense as a percentages of net sales, as reported	73.3 %	79.6 %
Reconciling items impacting selling, general and administrative expense:		
Transaction and transition costs - selling, general and administrative	2,287	10,560
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 127,547</b>	<b>\$ 124,186</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>72.0%</b>	<b>73.4%</b>
<b>Research &amp; development expense, as reported</b>	\$ 12,432	\$ 12,116
Research & development expense as a percentages of net sales, as reported	7.0 %	7.2 %
Reconciling items impacting research & development expense:		
Transaction and transition costs - research & development	—	149
<b>Research &amp; development expense, as adjusted</b>	<b>\$ 12,432</b>	<b>\$ 11,967</b>
<b>Research &amp; development expense as a percentage of net sales, as adjusted</b>	<b>7.0%</b>	<b>7.1%</b>